Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
暂无分享,去创建一个
M. Falavigna | T. Lisboa | R. Rosa | J. Dora | R. Breunig | A. Zavascki | E. Durigon | Almeri M Balsan | J. P. Portich | A. Paz | D. Sganzerla | L. Sekine | M. Sosnoski | Beatriz Arns | J. Pellegrini | P. Schwarz | M. V. Viana | R. Machado | É. Parolo | L. Silla | F. Volpato | Bruna R Fabro | Murillo M Cipolatt | Felipe da-Silva Schirmer | J. M. Franz | Luciana M da-Silveira | Viviana Petersen | N. F. Mesquita | E. Parolo
[1] S. Goodman,et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. , 2021, JAMA.
[2] D. Skovronsky,et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.
[3] Patrick W. Johnson,et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 , 2021, The New England journal of medicine.
[4] F. Polack,et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.
[5] Samuel M. Brown,et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 , 2020, The New England Journal of Medicine.
[6] D. Follmann,et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.
[7] V. Botosso,et al. SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network , 2020, Memorias do Instituto Oswaldo Cruz.
[8] T. Bhatnagar,et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) , 2020, BMJ.
[9] C. Soares,et al. Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program , 2020, Transfusion.
[10] P. Ashton-Prolla,et al. Pooling of samples to optimize SARS-CoV-2 diagnosis by RT-qPCR: comparative analysis of two protocols , 2020, European Journal of Clinical Microbiology & Infectious Diseases.
[11] Patrick W. Johnson,et al. Safety Update , 2020, Mayo Clinic Proceedings.
[12] L. Ren,et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[13] Jing Yuan,et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.
[14] D. Raoult,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.
[15] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[16] Arturo Casadevall,et al. The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.
[17] Sharon Einav,et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 , 2020, Journal of Critical Care.
[18] Philippe Brouqui,et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 , 2020, International Journal of Antimicrobial Agents.
[19] R. Rubin. HHS Funds Development of Antibiotic to Treat Anthrax. , 2020, JAMA.
[20] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[21] Jianjun Gao,et al. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.
[22] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[23] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[24] S. Lindstrom,et al. First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.
[25] Fang Li,et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.
[26] R. Schooley,et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial , 2019, The Lancet. Respiratory medicine.
[27] M. Müller,et al. Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience , 2018, Antiviral therapy.
[28] Lisa E. Gralinski,et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.
[29] J. Jorquera,et al. Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role , 2017, Expert review of anti-infective therapy.
[30] F. Hayden,et al. Emerging Blockininfectious Blockindiseases Blockin@bullet Blockin Feasibility of Using Convalescent Plasma Immunotherapy for Mers-cov Infection, Saudi Arabia , 2022 .
[31] Lanjuan Li,et al. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[32] W. Lim,et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.
[33] K. Yuen,et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. , 2013, Chest.
[34] D. Wendler,et al. A Framework for Risk-Benefit Evaluations in Biomedical Research , 2011, Kennedy Institute of Ethics journal.
[35] Kwok-Hung Chan,et al. Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] A. Casadevall,et al. Hark back: Passive immunotherapy for influenza and other serious infections , 2010, Critical care medicine.
[37] Disque Saúde. Guia para o uso de Hemocomponentes , 2010 .
[38] N. Ford,et al. Ethics of conducting research in conflict settings , 2009, Conflict and health.
[39] D. Schopper,et al. Research Ethics Review in Humanitarian Contexts: The Experience of the Independent Ethics Review Board of Médecins Sans Frontières , 2009, PLoS medicine.
[40] Samia Hurst,et al. Research Ethics and International Epidemic Response: The Case of Ebola and Marburg Hemorrhagic Fevers , 2009 .
[41] Gordon R Bernard,et al. Derivation and validation of Spo2/Fio2 ratio to impute for Pao2/Fio2 ratio in the respiratory component of the Sequential Organ Failure Assessment score* , 2009, Critical care medicine.
[42] M. Malinchoc,et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. , 2007, American journal of respiratory and critical care medicine.
[43] Y. Guan,et al. Treatment with convalescent plasma for influenza A (H5N1) infection. , 2007, The New England journal of medicine.
[44] L. Oyen. In Hospitalized Patients , 2007 .
[45] L. Kong,et al. Successful treatment of avian influenza with convalescent plasma. , 2006, Hong Kong medical journal = Xianggang yi xue za zhi.
[46] S. Hoffman,et al. Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? , 2006, Annals of Internal Medicine.
[47] P. Chan,et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital , 2005, The Journal of antimicrobial chemotherapy.
[48] H. Gao,et al. A serological survey on neutralizing antibody titer of SARS convalescent sera , 2005, Journal of medical virology.
[49] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[50] P. Chan,et al. Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[51] A. Casadevall,et al. Passive antibody therapy for infectious diseases , 2004, Nature Reviews Microbiology.
[52] J. Friedland,et al. Prevention of respiratory syncytial virus infection in infants , 2004, BMJ : British Medical Journal.
[53] Arturo Casadevall,et al. Antibody-mediated regulation of cellular immunity and the inflammatory response. , 2003, Trends in immunology.
[54] L. Pirofski,et al. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. , 2003, Current pharmaceutical design.
[55] J. Crowe,et al. Passively Acquired Antibodies Suppress Humoral But Not Cell-Mediated Immunity in Mice Immunized with Live Attenuated Respiratory Syncytial Virus Vaccines , 2001, The Journal of Immunology.
[56] A. Casadevall,et al. Serum therapy revisited: animal models of infection and development of passive antibody therapy , 1994, Antimicrobial Agents and Chemotherapy.
[57] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[58] A. Paychére. Mumps; use of convalescent serum in the treatment and prophylaxis of orchitis. , 1946, American journal of diseases of children.
[59] W. H. Park. THERAPEUTIC USE OF ANTIPOLIOMYELITIS SERUM IN PREPARALYTIC CASES OF POLIOMYELITIS , 1932 .
[60] R. G. Freeman,et al. THE PROPHYLACTIC USE OF MEASLES CONVALESCENT SERUM , 1926 .
[61] Behring,et al. Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren , 1890 .